Anteris Technologies Global Corp. — Board/Management Information 2025

Jun 9, 2025

==> picture [137 x 39] intentionally omitted <==

Board Appointments

MINNEAPOLIS, United States and BRISBANE, Australia 10 June 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces that on 7 June 2025 in USA / 8 June 2025 in Australia, the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) appointed Mr. Gregory Moss and Mr. David Roberts to serve on the Board. Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board. Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.

Mr. Gregory Moss, age 41, serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes.

Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia.

Mr David Roberts, age 61, is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc.

There are no understandings or arrangements between Mr. Moss and Mr. Roberts and any other person pursuant to which Mr. Moss or Mr. Roberts was selected to serve as a director of the Company. There are no relationships between Mr. Moss and Mr. Roberts and the Company or any of its subsidiaries that would require disclosure pursuant to Item 404(a) of Regulation S-K.

As non-employee directors, each of Mr. Moss and Mr. Roberts will receive cash and equity compensation in accordance with the Company’s Non-Employee Director Compensation Policy. Mr. Moss and Mr. Roberts will receive (A) on the date of their appointment, an initial equity grant consisting of restricted stock units (“RSUs”) with an aggregate grant date fair value of $US 250,000, which will vest in three substantially equal annual installments subject to their continued service on the Board through such dates and which grant will be subject to stockholder approval in accordance with the rules of the Australian Securities Exchange; and

==> picture [28 x 30] intentionally omitted <==

Anteris Technologies Global Corp. BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

860 Blue Gentian Road, Suite 340 Eagan, MN, 55121 United States T: +1 651 493 0606 info.us@anteristech.com

Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong QLD 4066, Australia T: +61 1300 550 310 info.au@anteristech.com ARBN: 677 960 235

anteristech.com

==> picture [117 x 33] intentionally omitted <==

(B) annual cash retainers, payable in monthly installments and prorated for any portion of a month that they are not serving in such positions on the Board or its committees. Further, in accordance with the Company’s Non-Employee Director Compensation Policy, as non-employee directors having served less than six months prior to the Company’s 2025 annual meeting of stockholders, Mr. Moss and Mr. Roberts will each be eligible to receive a prorated annual grant of RSUs, subject to stockholder approval in accordance with the rules of the Australian Securities Exchange, which will vest on the earlier to occur of the first anniversary of the grant date or the date of the Company’s next annual stockholder meeting, subject to their continued service on the Board through such date.

Effective 7 June 2025 in USA / 8 June 2025 in Australia, the Company entered into indemnification agreements with each of Mr. Moss and Mr. Roberts in the form previously filed as Exhibit 10.2 to the Company’s Form S-1 filed with the Securities and Exchange Commission on November 22, 2024. The indemnification agreement requires the Company to indemnify each of Mr. Moss and Mr. Roberts to the fullest extent permitted under Delaware law against liability that may arise by reason of their service to the Company, and to advance expenses incurred as a result of any proceedings against them as to which they could be indemnified, among other things.

Resignation of Dr. Wenyi Gu from the Board of Directors

On 5 June 2025 in USA / 6 June 2025 in Australia, Dr. Wenyi Gu resigned from the Board and as a Class III director with immediate effect. The resignation from the Board was not due to any disagreement with the Company or its management with respect to any matter relating to the Company’s operations, policies or practices.

The Board thanks Wenyi for his contribution.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a sciencedriven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR[®] Transcatheter Heart Valve ( THV ), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially lifethreatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[® ] THV is made using a single piece of molded ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

==> picture [28 x 31] intentionally omitted <==

2

==> picture [117 x 33] intentionally omitted <==

For more information:

Investor Relations

investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269

Website www.anteristech.com X @AnterisTech LinkedIn https://www.linkedin.com/company/anteristech

==> picture [28 x 31] intentionally omitted <==

3